Reply to 'Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials': reply from the authors

摘要

Dear Editor, We would like to thank Drs Amin, No and Wu for their interest1 in our recent publication,2 We are pleased to note, in particular, how much we agree on one fundamental point - there is a need for future well-designed studies that involve larger numbers of patients and longer durations of treatment exposure in order to better assess the impact of biologic therapies on the risk of major adverse cardiovascular events (MACEs) in patients with psoriasis. In our paper, we present Peto odds ratios for MACEs in patients treated with (i) all biologic therapies vs. placebo, (ii) tumour necrosis factor-a inhibitors (TNFi) vs. placebo, (iii) anti-interleukin-(IL)-17A agents vs. placebo and (iv) ustek-inumab vs. placebo. On the basis of these comparisons, we clearly concluded that the limited existing evidence suggests that licensed biologic therapies are not associated with MACEs during the short randomized controlled periods in the published clinical trials.